# Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

> **NCT00568945** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 28 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Capadenoson (BAY68-4986)

## Key facts

- **NCT ID:** NCT00568945
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-11
- **Final completion:** 2008-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568945, "Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00568945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*